Karima Djabali

Publication Activity (10 Years)

Years Active: 2016-2024
Publications (10 Years): 8

Top Topics

Cardiovascular Risk Factors

Genome Wide Analysis

Top Venues

International journal of molecular sciences

Pharmaceuticals (Basel, Switzerland)

This page only lists publications with an associated author ORCID identifier.

Publications

Peter Krüger, Ramona Hartinger, Karima Djabali
Navigating Lipodystrophy: Insights from Laminopathies and Beyond. International journal of molecular sciences 25 (15) (2024)
Peter Krüger, Moritz Schroll, Felix Fenzl, Eva-Maria Lederer, Ramona Hartinger, Rouven Arnold, Deniz Cagla Togan, Runjia Guo, Shiyu Liu, Andreas Petry, Agnes Görlach, Karima Djabali
Inflammation and Fibrosis in Progeria: Organ-Specific Responses in an HGPS Mouse Model. International journal of molecular sciences 25 (17) (2024)
Peter Krüger, Ramona Hartinger, Karima Djabali
Navigating Lipodystrophy: Insights from Laminopathies and Beyond. International journal of molecular sciences 25 (15) (2024)
Ramona Hartinger, Eva-Maria Lederer, Elisa Schena, Giovanna Lattanzi, Karima Djabali
Impact of Combined Baricitinib and FTI Treatment on Adipogenesis in Hutchinson-Gilford Progeria Syndrome and Other Lipodystrophic Laminopathies. Cells 12 (10) (2023)
Elena Vehns, Rouven Arnold, Karima Djabali
Impact of MnTBAP and Baricitinib Treatment on Hutchinson-Gilford Progeria Fibroblasts. Pharmaceuticals (Basel, Switzerland) 15 (8) (2022)
Rouven Arnold, Elena Vehns, Hannah Randl, Karima Djabali
Baricitinib, a JAK-STAT Inhibitor, Reduces the Cellular Toxicity of the Farnesyltransferase Inhibitor Lonafarnib in Progeria Cells. International journal of molecular sciences 22 (14) (2021)
Leithe Budel, Karima Djabali
Rapid isolation and expansion of skin-derived precursor cells from human primary fibroblast cultures. Biology open 6 (11) (2017)
Diana Gabriel, Leslie B Gordon, Karima Djabali
Temsirolimus Partially Rescues the Hutchinson-Gilford Progeria Cellular Phenotype. PloS one 11 (12) (2016)